Inovio Pharmaceuticals
About: Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Employees: 122
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
35% more call options, than puts
Call options by funds: $1.71M | Put options by funds: $1.27M
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
30% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 20
1.5% more ownership
Funds ownership: 31.54% [Q2] → 33.04% (+1.5%) [Q3]
1% more funds holding
Funds holding: 96 [Q2] → 97 (+1) [Q3]
25% less capital invested
Capital invested by funds: $66M [Q2] → $49.6M (-$16.5M) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
36%
upside
Avg. target
$10.50
377%
upside
High target
$18
718%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju 37% 1-year accuracy 118 / 316 met price target | 36%upside $3 | Neutral Maintained | 13 Jan 2025 |
JMP Securities Roy Buchanan 31% 1-year accuracy 5 / 16 met price target | 718%upside $18 | Market Outperform Reiterated | 10 Jan 2025 |
Oppenheimer Jay Olson 22% 1-year accuracy 23 / 104 met price target | 582%upside $15 | Outperform Maintained | 18 Nov 2024 |
RBC Capital Gregory Renza 30% 1-year accuracy 26 / 86 met price target | 173%upside $6 | Sector Perform Maintained | 15 Nov 2024 |
Financial journalist opinion
Neutral
PRNewsWire
1 week ago
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
PLYMOUTH MEETING, Pa. , Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings.
Positive
Benzinga
2 weeks ago
Top 3 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Negative
Benzinga
1 month ago
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet
U.S. stocks traded mixed toward the end of trading, with the S&P 500 edging lower on Friday.
Neutral
PRNewsWire
1 month ago
INOVIO Announces Pricing of $30 Million Public Offering
PLYMOUTH MEETING, Pa. , Dec. 13, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock and accompanying warrants to purchase 10,000,000 shares of its common stock at an exercise price of $3.76 per share of common stock, at a combined public offering price of $3.00 per share of common stock and accompanying warrant.
Neutral
PRNewsWire
1 month ago
INOVIO Announces Proposed Public Offering
PLYMOUTH MEETING, Pa. , Dec. 12, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock, in an underwritten public offering.
Neutral
PRNewsWire
1 month ago
New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial
Data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) involved in a Phase 1/2 trial showed the number of patients who met the criteria for a Complete Response (CR) increased to 50% by the end of year 2 and to 54% in year 3, compared to 28% by the end of the initial 52-week trial 95% of patients in the retrospective trial (RRP-002) maintained or enhanced their original Overall Response Rate (ORR) reported in the Phase 1/2 trial (RRP-001) by the end of year 2; 86% of patients maintained or enhanced ORR into year 3 New durability data will help inform re-dosing strategy focused on long-term elimination or reduction in the need for surgery to treat RRP disease INOVIO plans to present data at future scientific conferences and submit for publication in peer-reviewed journals PLYMOUTH MEETING, Pa. , Dec. 3, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced data from a retrospective trial showing that the number of RRP patients meeting the criteria for a Complete Response increased to 50% by the end of the second year following initial treatment with INO-3107 in a previously reported Phase 1/2 52-week trial where the Complete Response rate was 28%.
Neutral
PRNewsWire
1 month ago
INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa. , Nov. 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
Negative
Benzinga
2 months ago
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
Neutral
Seeking Alpha
2 months ago
Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2024 Earnings Call Transcript November 14, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of IR Jacqui Shea - President and CEO Mike Sumner - CMO Steve Egge - CCO Peter Kies - CFO Matthew Morrow - VP of Translational Sciences Conference Call Participants Jay Olson - Oppenheimer Roy Buchanan - Citizens JMP Sudan Loganathan - Stephens Liang Cheng - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode.
Neutral
PRNewsWire
2 months ago
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights
New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma Data showed INO-3107 induced expansion of new clonal T cells that infiltrate airway tissues and correspond with reduction of surgeries for RRP patients observed in Phase 1/2 trial Continued progress on preparing regulatory submissions for INO-3107 All non-device BLA modules on track for completion by end of 2024 BLA submission remains targeted for mid-2025 PLYMOUTH MEETING, Pa. , Nov. 14, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the third quarter of 2024 and provided an update on recent company developments.
Charts implemented using Lightweight Charts™